AR006616A1 - Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen - Google Patents

Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen

Info

Publication number
AR006616A1
AR006616A1 ARP970101461A ARP970101461A AR006616A1 AR 006616 A1 AR006616 A1 AR 006616A1 AR P970101461 A ARP970101461 A AR P970101461A AR P970101461 A ARP970101461 A AR P970101461A AR 006616 A1 AR006616 A1 AR 006616A1
Authority
AR
Argentina
Prior art keywords
inhibitors
receptors
endothelins
pharmaceutical compositions
compositions containing
Prior art date
Application number
ARP970101461A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR006616A1 publication Critical patent/AR006616A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a derivados de carboxílicos de la fórmula (I) donde los restos poseen el significado definido en la descripción, a la preparaciónde estos compuestos y a su aplicación como medicamentos. Dichos derivados son útiles comoinhib idores de receptores de la endotelina, de reducida uniónendoplamática.
ARP970101461A 1996-04-12 1997-04-11 Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen AR006616A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19614534A DE19614534A1 (de) 1996-04-12 1996-04-12 Neue Carbonsäurederivate, ihre Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
AR006616A1 true AR006616A1 (es) 1999-09-08

Family

ID=7791118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101461A AR006616A1 (es) 1996-04-12 1997-04-11 Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen

Country Status (26)

Country Link
US (1) US6610691B1 (es)
EP (1) EP0892786B1 (es)
JP (1) JP2000508324A (es)
KR (1) KR20000005367A (es)
CN (1) CN1216041A (es)
AR (1) AR006616A1 (es)
AT (1) ATE268760T1 (es)
AU (1) AU714717B2 (es)
BG (1) BG63201B1 (es)
BR (1) BR9708609A (es)
CA (1) CA2251381A1 (es)
CO (1) CO4900039A1 (es)
CZ (1) CZ324798A3 (es)
DE (2) DE19614534A1 (es)
HR (1) HRP970199A2 (es)
HU (1) HUP9901315A3 (es)
ID (1) ID16824A (es)
IL (1) IL126027A0 (es)
NO (1) NO311571B1 (es)
NZ (1) NZ331735A (es)
PL (1) PL329238A1 (es)
SK (1) SK133998A3 (es)
TR (1) TR199802044T2 (es)
TW (1) TW426672B (es)
WO (1) WO1997038980A1 (es)
ZA (1) ZA973098B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275256A1 (en) * 1996-12-18 1998-06-25 Basf Aktiengesellschaft Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
ID24278A (id) * 1997-10-31 2000-07-13 Basf Ag Turunan-turunan asam karboksilat baru dengan rantai sisi amida, pembuatan dan penggunaannya sebagai reseptor antagonis endotelin
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE10025728A1 (de) * 2000-05-25 2001-11-29 Basf Ag Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US8008351B2 (en) 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1781276B1 (en) 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1910272A4 (en) 2005-07-22 2010-08-04 Merck Frosst Canada Ltd INHIBITORS OF THE RENINE
EA027836B1 (ru) 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053603A1 (en) * 1990-10-19 1992-04-20 Katsumasa Harada 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
BR9708609A (pt) 1999-08-03
NO984714L (no) 1998-10-09
HUP9901315A2 (hu) 1999-08-30
SK133998A3 (en) 1999-03-12
BG102814A (en) 1999-11-30
EP0892786A1 (de) 1999-01-27
WO1997038980A1 (de) 1997-10-23
NO311571B1 (no) 2001-12-10
PL329238A1 (en) 1999-03-15
KR20000005367A (ko) 2000-01-25
ZA973098B (en) 1998-10-12
EP0892786B1 (de) 2004-06-09
BG63201B1 (bg) 2001-06-29
US6610691B1 (en) 2003-08-26
CZ324798A3 (cs) 1999-04-14
TR199802044T2 (xx) 1999-02-22
IL126027A0 (en) 1999-05-09
ATE268760T1 (de) 2004-06-15
NZ331735A (en) 2000-06-23
AU2294097A (en) 1997-11-07
NO984714D0 (no) 1998-10-09
AU714717B2 (en) 2000-01-06
CO4900039A1 (es) 2000-03-27
DE19614534A1 (de) 1997-10-16
CA2251381A1 (en) 1997-10-23
HRP970199A2 (en) 1998-06-30
JP2000508324A (ja) 2000-07-04
TW426672B (en) 2001-03-21
ID16824A (id) 1997-11-13
DE59711704D1 (de) 2004-07-15
CN1216041A (zh) 1999-05-05
HUP9901315A3 (en) 2000-03-28

Similar Documents

Publication Publication Date Title
AR006616A1 (es) Derivados carboxilicos utiles como inhibidores de los receptores de las endotelinas y composiciones farmaceuticas que los contienen
BR9916894A (pt) ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
AU2002224885A1 (en) Morpholine derivatives as antagonists of orexin receptors
ES2189256T3 (es) Composiciones de mezclas de ester de cianoacrilato.
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
ECSP034462A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
DE69625354D1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR0111678A (pt) Composições medicinais contendo derivados de propenona
YU4197A (sh) Smeše koje se mogu izolovati polazeći od semena eugenia jambolana lamarck, njihovo dobijanje i primena ovih smeša i nekih od njihovih sastojaka kao lekova
CY1105482T1 (el) Χρηση της αζιθρομυκινης στην τοπικη αγωγη οφθαλμικων μολυνσεων
SE9901077D0 (sv) Novel use
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PT1105114E (pt) Composicoes farmaceuticas topicas contendo nimesulide
SE9801494D0 (sv) Novel use
DE69525740T2 (de) Spezielle halofantrinhaltige Zusammensetzungen
ES2139669T3 (es) Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure